These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2846 related articles for article (PubMed ID: 24714771)

  • 1. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
    Taube JM; Klein A; Brahmer JR; Xu H; Pan X; Kim JH; Chen L; Pardoll DM; Topalian SL; Anders RA
    Clin Cancer Res; 2014 Oct; 20(19):5064-74. PubMed ID: 24714771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
    Yi M; Jiao D; Xu H; Liu Q; Zhao W; Han X; Wu K
    Mol Cancer; 2018 Aug; 17(1):129. PubMed ID: 30139382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
    You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
    Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    Topalian SL; Hodi FS; Brahmer JR; Gettinger SN; Smith DC; McDermott DF; Powderly JD; Carvajal RD; Sosman JA; Atkins MB; Leming PD; Spigel DR; Antonia SJ; Horn L; Drake CG; Pardoll DM; Chen L; Sharfman WH; Anders RA; Taube JM; McMiller TL; Xu H; Korman AJ; Jure-Kunkel M; Agrawal S; McDonald D; Kollia GD; Gupta A; Wigginton JM; Sznol M
    N Engl J Med; 2012 Jun; 366(26):2443-54. PubMed ID: 22658127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
    Taube JM; Young GD; McMiller TL; Chen S; Salas JT; Pritchard TS; Xu H; Meeker AK; Fan J; Cheadle C; Berger AE; Pardoll DM; Topalian SL
    Clin Cancer Res; 2015 Sep; 21(17):3969-76. PubMed ID: 25944800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.
    Sridharan V; Gjini E; Liao X; Chau NG; Haddad RI; Severgnini M; Hammerman P; El-Naggar A; Freeman GJ; Hodi FS; Rodig SJ; Dranoff G; Schoenfeld JD
    Cancer Immunol Res; 2016 Aug; 4(8):679-87. PubMed ID: 27312343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
    Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
    Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.
    Stevenson ML; Wang CQ; Abikhair M; Roudiani N; Felsen D; Krueger JG; Pavlick AC; Carucci JA
    JAMA Dermatol; 2017 Apr; 153(4):299-303. PubMed ID: 28259107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
    BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
    He Y; Liu S; Mattei J; Bunn PA; Zhou C; Chan D
    Drug Des Devel Ther; 2018; 12():981-986. PubMed ID: 29731605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 143.